Tout DSpace

Afficher la notice abrégée

Medical management of gastric cancer: a 2017 update

dc.creatorCharalampakis N., Economopoulou P., Kotsantis I., Tolia M., Schizas D., Liakakos T., Elimova E., Ajani J.A., Psyrri A.en
dc.date.accessioned2023-01-31T07:43:08Z
dc.date.available2023-01-31T07:43:08Z
dc.date.issued2018
dc.identifier10.1002/cam4.1274
dc.identifier.issn20457634
dc.identifier.urihttp://hdl.handle.net/11615/72519
dc.description.abstractGastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence-based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer. © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.en
dc.language.isoenen
dc.sourceCancer Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85037984167&doi=10.1002%2fcam4.1274&partnerID=40&md5=0e8af18db64343e627b4a6f88868d99e
dc.subjectadvanced canceren
dc.subjectcancer risken
dc.subjectcancer surgeryen
dc.subjectchemoradiotherapyen
dc.subjecthumanen
dc.subjectmetastasisen
dc.subjectmultimodality cancer therapyen
dc.subjectperioperative perioden
dc.subjectphase 3 clinical trial (topic)en
dc.subjectpostoperative careen
dc.subjectprimary health careen
dc.subjectpriority journalen
dc.subjectReviewen
dc.subjectsecondary health careen
dc.subjectstomach canceren
dc.subjecttertiary health careen
dc.subjectadjuvant chemotherapyen
dc.subjectantagonists and inhibitorsen
dc.subjectgastrectomyen
dc.subjectgeneticsen
dc.subjectglobal disease burdenen
dc.subjectmolecularly targeted therapyen
dc.subjectproceduresen
dc.subjectprognosisen
dc.subjectrandomized controlled trial (topic)en
dc.subjectstomach tumoren
dc.subjectantineoplastic agenten
dc.subjecttumor markeren
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen
dc.subjectBiomarkers, Tumoren
dc.subjectChemotherapy, Adjuvanten
dc.subjectClinical Trials, Phase III as Topicen
dc.subjectGastrectomyen
dc.subjectGlobal Burden of Diseaseen
dc.subjectHumansen
dc.subjectMolecular Targeted Therapyen
dc.subjectPrognosisen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectStomach Neoplasmsen
dc.subjectBlackwell Publishing Ltden
dc.titleMedical management of gastric cancer: a 2017 updateen
dc.typeotheren


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée